110.13
price down icon1.36%   -1.57
after-market 시간 외 거래: 110.73 0.60 +0.54%
loading
전일 마감가:
$111.70
열려 있는:
$111.44
하루 거래량:
1.66M
Relative Volume:
0.71
시가총액:
$219.89B
수익:
$53.22B
순이익/손실:
$12.86B
주가수익비율:
17.23
EPS:
6.39
순현금흐름:
$14.85B
1주 성능:
-1.03%
1개월 성능:
+8.06%
6개월 성능:
+3.50%
1년 성능:
+10.62%
1일 변동 폭
Value
$109.77
$111.44
1주일 범위
Value
$109.77
$114.88
52주 변동 폭
Value
$96.06
$120.92

노바티스 ADR Stock (NVS) Company Profile

Name
명칭
Novartis Ag Adr
Name
전화
-
Name
주소
-
Name
직원
75,883
Name
트위터
@novartis
Name
다음 수익 날짜
2025-01-31
Name
최신 SEC 제출 서류
Name
NVS's Discussions on Twitter

NVS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
110.13 219.89B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
LLY
Lilly Eli Co
751.45 681.85B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
155.66 370.90B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.58 342.01B 57.37B 4.20B 17.83B 2.35
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
64.85 291.20B 42.09B 14.65B 10.11B 3.2833

노바티스 ADR Stock (NVS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-13 다운그레이드 UBS Buy → Neutral
2025-02-12 개시 Morgan Stanley Underweight
2025-02-04 업그레이드 Deutsche Bank Hold → Buy
2024-12-04 다운그레이드 HSBC Securities Hold → Reduce
2024-09-11 다운그레이드 BofA Securities Buy → Neutral
2024-09-05 다운그레이드 Goldman Buy → Neutral
2024-09-03 다운그레이드 Jefferies Buy → Hold
2024-07-19 다운그레이드 Deutsche Bank Buy → Hold
2024-05-30 개시 Goldman Buy
2024-02-23 개시 BMO Capital Markets Market Perform
2024-01-23 개시 Morgan Stanley Equal-Weight
2024-01-16 재개 UBS Buy
2023-12-18 다운그레이드 HSBC Securities Buy → Hold
2023-09-25 업그레이드 Morgan Stanley Underweight → Equal-Weight
2023-07-14 개시 HSBC Securities Buy
2023-04-26 업그레이드 Deutsche Bank Hold → Buy
2023-03-27 업그레이드 Deutsche Bank Sell → Hold
2023-01-26 다운그레이드 Citigroup Buy → Neutral
2022-12-05 업그레이드 Stifel Hold → Buy
2022-09-15 다운그레이드 Credit Suisse Neutral → Underperform
2022-09-14 다운그레이드 Berenberg Buy → Hold
2022-05-09 다운그레이드 Wolfe Research Outperform → Peer Perform
2022-01-10 재개 Citigroup Buy
2021-12-14 다운그레이드 Redburn Buy → Neutral
2021-12-06 다운그레이드 Exane BNP Paribas Outperform → Neutral
2021-12-03 다운그레이드 Bryan Garnier Buy → Neutral
2021-09-20 다운그레이드 Deutsche Bank Hold → Sell
2021-03-22 개시 Bernstein Mkt Perform
2021-03-10 다운그레이드 Argus Buy → Hold
2021-02-01 다운그레이드 Cowen Outperform → Market Perform
2021-01-15 개시 Deutsche Bank Buy
2020-09-29 개시 Berenberg Buy
2020-09-10 업그레이드 UBS Neutral → Buy
2020-09-01 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-06-15 업그레이드 Citigroup Neutral → Buy
2020-03-10 업그레이드 Morgan Stanley Underweight → Equal-Weight
2020-02-25 다운그레이드 Guggenheim Buy → Neutral
2019-04-25 업그레이드 Guggenheim Neutral → Buy
2019-04-25 업그레이드 Liberum Hold → Buy
2019-04-10 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2019-01-02 다운그레이드 JP Morgan Neutral → Underweight
2018-12-11 재개 Jefferies Buy
2018-10-09 개시 Guggenheim Neutral
2018-09-10 업그레이드 BofA/Merrill Underperform → Buy
2018-05-29 다운그레이드 HSBC Securities Buy → Hold
2018-05-25 업그레이드 Credit Suisse Underperform → Neutral
2018-01-25 재확인 Leerink Partners Outperform
2017-12-06 다운그레이드 BofA/Merrill Neutral → Underperform
2017-07-26 업그레이드 Morgan Stanley Underweight → Overweight
2017-07-05 다운그레이드 Credit Suisse Neutral → Underperform
2017-03-09 개시 Liberum Buy
모두보기

노바티스 ADR 주식(NVS)의 최신 뉴스

pulisher
10:55 AM

Contract Research and Manufacturing Services (CRAMS) Business Report 2025: Market to Reach $211.4 Billion by 2030, Fueled by Growing Demand for Biologics and Biosimilars - GlobeNewswire Inc.

10:55 AM
pulisher
May 02, 2025

NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com

May 02, 2025
pulisher
Apr 29, 2025

Novartis Earnings: Strong First-Quarter Supports Increased Full-Year Guidance - Morningstar

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis ADR earnings beat by $0.20, revenue topped estimates - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis Beats On Q1 Earnings And Sales, Raises Guidance, Stock Up - Barchart.com

Apr 29, 2025
pulisher
Apr 22, 2025

Roche to invest US$50-billion in U.S. to avoid Trump tariffs, create 12,000 jobs - The Globe and Mail

Apr 22, 2025
pulisher
Apr 21, 2025

Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? - Yahoo Finance

Apr 21, 2025
pulisher
Apr 11, 2025

Swiss pharmaceutical giant announces plans for $1.1B campus in San Diego - fox5sandiego.com

Apr 11, 2025
pulisher
Apr 11, 2025

Stocks to Watch Friday: JPMorgan, Wells Fargo, BlackRock, Newmont - WSJ

Apr 11, 2025
pulisher
Apr 04, 2025

Pharma Stock Roundup: FDA Nod To SNY, AZN & NVS, JNJ Talc Suits Failure - Barchart.com

Apr 04, 2025
pulisher
Apr 03, 2025

FDA Grants Accelerated Approval To NVS Kidney Disease Drug - Barchart.com

Apr 03, 2025
pulisher
Apr 03, 2025

Quantum Corp’s Banking’s 100-Day Moving Average at 21.57: Will the Stock Break Through? - investchronicle.com

Apr 03, 2025
pulisher
Mar 26, 2025

No room on the ARK? - Morningstar

Mar 26, 2025
pulisher
Mar 25, 2025

5 Large Drug Stocks To Watch As Industry Recovers - Barchart

Mar 25, 2025
pulisher
Mar 21, 2025

FDA Approves Novartis Drug For Rare Kidney Disease Treatment - Barchart

Mar 21, 2025
pulisher
Mar 19, 2025

Novartis scraps use of diverse panels for hires in US - Reuters

Mar 19, 2025
pulisher
Mar 14, 2025

Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart

Mar 14, 2025
pulisher
Mar 13, 2025

Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.

Mar 13, 2025
pulisher
Mar 12, 2025

Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.

Mar 12, 2025
pulisher
Mar 07, 2025

Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™ - Barchart

Mar 07, 2025
pulisher
Mar 07, 2025

Giovanni Caforio, M.D. - Novartis

Mar 07, 2025
pulisher
Mar 05, 2025

Novartis Near Buy Point; Earns Near-Best Overall Rating - Investor's Business Daily

Mar 05, 2025
pulisher
Mar 04, 2025

META_TITLE_QUOTE - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Novartis Earnings Surprised The Street; Still Going Strong - Investor's Business Daily

Mar 04, 2025
pulisher
Mar 03, 2025

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta - Yahoo Finance

Mar 03, 2025
pulisher
Feb 26, 2025

AZN: 3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine - StockNews.com

Feb 26, 2025
pulisher
Feb 25, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Feb 25, 2025
pulisher
Feb 21, 2025

NVS: 3 Gene Therapy Stocks With Game-Changing Potential - StockNews.com

Feb 21, 2025
pulisher
Feb 18, 2025

NVS Quantitative Stock Analysis - Nasdaq

Feb 18, 2025
pulisher
Feb 16, 2025

Novartis: Strong Execution With A P/E Discount (NYSE:NVS) - Seeking Alpha

Feb 16, 2025
pulisher
Feb 13, 2025

Company’s Banking Stock: Dissecting a 2.21% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Feb 13, 2025

노바티스 ADR (NVS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general MRK
$77.65
price down icon 1.83%
drug_manufacturers_general NVO
$64.85
price down icon 3.99%
$272.05
price down icon 1.38%
drug_manufacturers_general PFE
$22.97
price up icon 0.70%
drug_manufacturers_general SNY
$52.13
price down icon 0.27%
자본화:     |  볼륨(24시간):